Use of Acitretin Among Girls and Women of Childbearing Age and Occurrence of Acitretin-Exposed Pregnancies in Germany
Open Access
- 31 October 2023
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (11) , 865-872
Abstract
Background and Objective Acitretin has long-lasting teratogenic properties. Therefore, pregnancies must be avoided during and within 3 years after acitretin treatment. We aimed to describe (i) acitretin use in women of childbearing age in Germany, (ii) the occurrence of acitretin-exposed pregnancies, and (iii) malformations among children exposed in utero. Methods Using 2004–2019 data from the German Pharmacoepidemiological Research Database (GePaRD—claims data from ~ 20% of the German population), we determined annual age-standardized prevalence of acitretin use among girls and women aged 13–49 years. In longitudinal analyses, we estimated the number of exposed pregnancies by assessing whether the exposure window assigned to the last dispensation before pregnancy (days covered by dispensation plus 3 years) overlapped the onset of pregnancy or whether there was a dispensation in the first eight weeks of pregnancy. Data of live-born children with in utero exposure to acitretin were reviewed to assess the presence of congenital malformations. Results The age-standardized prevalence of acitretin use per 1000 girls and women was 0.04 in 2019. We identified 35 acitretin-exposed pregnancies; 94.3% of these pregnancies were classified as exposed because they occurred within 3 years after stopping acitretin treatment. Among 18 live-born children linked to their mother, four children (22.2%) had congenital malformations (three children with a major malformation). Conclusions We observed 35 acitretin-exposed pregnancies mainly because treatment ended too late before pregnancy. Approximately one in five children born from these pregnancies had malformations, highlighting the importance of drawing more attention to the long-lasting teratogenicity of this drug.Keywords
Funding Information
- Bundesinstitut für Arzneimittel und Medizinprodukte (V-18281/ 68605 / 2019-2020)
- Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH
This publication has 21 references indexed in Scilit:
- Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretinPharmacoepidemiology and Drug Safety, 2015
- Intended and Unintended Pregnancies Worldwide in 2012 and Recent TrendsStudies in Family Planning, 2014
- Acitretin prescribing patterns in women of childbearing potential.2013
- Evaluation of pregnancy outcome records in the German Pharmacoepidemiological Research Database (GePaRD)Pharmacoepidemiology and Drug Safety, 2013
- Linkage of mother–baby pairs in the German Pharmacoepidemiological Research DatabasePharmacoepidemiology and Drug Safety, 2010
- Acitretin embryopathy: A case reportBirth Defects Research Part A: Clinical and Molecular Teratology, 2004
- Teratogenic Risk with Etretinate and Acitretin TreatmentDermatology, 1994
- Acitretin. A review of its pharmacology and therapeutic use.1992
- AcitretinDrugs, 1992
- Teratogene Wirkung von Etretinat beim MenschenDMW - Deutsche Medizinische Wochenschrift, 1984